Diabetes mellitus (DM) is prevalent in patients with
pancreatic cancer and tends to improve after
tumor resection. However, the glycemic response of non-
pancreatic cancer patients after surgery has not been examined in detail. We aimed to investigate the changes in
glucose metabolism in patients with
pancreatic cancer or non-
pancreatic cancer after
pancreatoduodenectomy (PD).We prospectively enrolled 48 patients with
pancreatic cancer and 56 patients with non-
pancreatic cancer, who underwent PD.
Glucose metabolism was assessed with fasting
glucose,
glycated hemoglobin (HbA1c), plasma
C-peptide and
insulin, quantitative
insulin check index (QUICKI), and a homeostatic model assessment of
insulin resistance (HOMA-IR) and β cell (HOMA-β) before surgery and 6 months after surgery. Patients were divided into 2 groups: "improved" and "worsened" postoperative glycemic response, according to the changes in HbA1c and anti-diabetic medication. New-onset DM was defined as diagnosis of DM ≤ 2 years before PD, and cases with DM diagnosis >2 years preceding PD were described as long-standing DM.After PD,
insulin resistance (IR), as measured by
insulin, HOMA-IR and QUICKI, improved significantly, although
C-peptide and HOMA-β decreased. At 6 months after PD, new-onset DM patients showed improved
glycemic control in both
pancreatic cancer patients (75%) and non-
pancreatic cancer patients (63%). Multivariate analysis showed that long-standing DM was a significant predictor for worsening
glucose control (odds ratio = 4.01, P = .017).Favorable
glycemic control was frequently observed in both
pancreatic cancer and non-
pancreatic cancer after PD. PD seems to contribute improved
glucose control through the decreased IR. New-onset DM showed better
glycemic control than long-standing DM.